Systems and methods for measuring cell signaling protein activity
US-2024230643-A9 · Jul 11, 2024 · US
GLUT-1 as a receptor for HTLV envelopes and its uses
US8945583B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945583-B2 |
| Application number | US-54792409-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 26, 2009 |
| Priority date | May 2, 2003 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating solid tumors overexpressing GLUT1 on cell surfaces, said method comprising administering to a subject in need thereof an effective amount of a GLUT1 binding polypeptide, wherein, said GLUT1 binding polypeptide comprises an envelope protein selected from the group consisting of HTLV-1, HTLV-2, STLV-1, STLV-2 or STLV-3, or a fragment thereof, wherein said fragment has an N-terminal located between positions 1 to 90, and a C-termin…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945583B2 cover?
- The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linke…
- Who is the assignee on this patent?
- Battini Jean-Luc Georges Laurent, Manel Nicolas Gabriel Albert, Kim Felix Jinhyun, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/566. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).